Certain New Chemicals; Receipt and Status Information for April 2024
EPA published receipt and status information for certain new chemicals under TSCA for April 2024. This is a routine procedural update and does not directly affect med-spa operations or compliance requirements.
Aforeworn detected this change in the Med-Spa & Aesthetics Clinics space on July 6, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Low urgency. Med-spa and aesthetics clinics using chemicals regulated under TSCA (e.g., certain solvents, cleaning agents, or cosmetic ingredients). should confirm how it applies to their specific situation before acting. There is a time constraint attached: None. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Med-Spa & Aesthetics Clinics continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
EPA published a list of new chemical submissions and their statuses for April 2024. No new regulations or enforcement actions were introduced.
Who it affects
Med-spa and aesthetics clinics using chemicals regulated under TSCA (e.g., certain solvents, cleaning agents, or cosmetic ingredients).
What you must do
No immediate action required. Review the list to ensure any new chemicals used in your practice are not subject to additional restrictions.
Deadline
None
Never miss a change like this again
Aforeworn watches Med-Spa & Aesthetics Clinics around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Med-Spa & Aesthetics Clinics
- FDA Approves Labeling Changes for Over-the-Counter (OTC) Weight Loss Drug alli (Orlistat) to Warn of Risk of Kidney Stones and Kidney Injury
- Accolade Pacemaker Devices by Boston Scientific and Potential Need for Early Device Replacement - FDA Safety Communication
- Heart Pump Correction: Abiomed Issues Correction for Automated Impella Controllers
- Disruptions in Availability of Breast Biopsy Needles - Letter to Health Care Providers
- UPDATE: Hintermann Series H3 Total Ankle Replacement Has a Higher-Than-Expected Risk of Device Failure: FDA Safety Communication